Equillium (NASDAQ:EQ) Given New $5.00 Price Target at HC Wainwright

Equillium (NASDAQ:EQFree Report) had its target price boosted by HC Wainwright from $4.00 to $5.00 in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Equillium Stock Up 3.3 %

Shares of NASDAQ:EQ opened at $2.18 on Tuesday. The company has a market cap of $76.87 million, a price-to-earnings ratio of -5.59 and a beta of 1.62. The firm’s 50-day simple moving average is $2.07 and its 200-day simple moving average is $1.15. Equillium has a fifty-two week low of $0.45 and a fifty-two week high of $3.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its position in shares of Equillium by 13.2% in the first quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after purchasing an additional 6,564 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Equillium by 56.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 31,339 shares of the company’s stock worth $33,000 after buying an additional 11,339 shares in the last quarter. Jane Street Group LLC acquired a new stake in Equillium during the first quarter worth $47,000. Renaissance Technologies LLC acquired a new stake in Equillium during the second quarter worth $34,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Equillium in the 3rd quarter valued at $43,000. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Company Profile

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

Read More

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.